BridgeBio Oncology Therapeutics, Inc.

10-Year Study

BBOT.US · Healthcare · US · Common Stock

Executive Summary: BridgeBio Oncology Therapeutics, Inc. has compounded at -5.2% annually over the last 10 years, with a maximum drawdown of 28.5% and an annualized volatility of 116.0%.

1Y CAGR
-15.4%
3Y CAGR
-5.2%
5Y CAGR
-5.2%
10Y CAGR
-5.2%

History & Riski10-year historical performance analysis including CAGR, Max Drawdown, Sharpe & Sortino ratios, annual returns, and rolling volatility — all computed from daily market data.

10-Year Growth of $10,000

Max DrawdownMax DrawdownThe largest peak-to-trough decline in the asset's value over the measurement period.Click for full definition →
28.5%
Sharpe RatioSharpe RatioRisk-adjusted return: how much excess return you earn per unit of total risk (volatility).Click for full definition →
-0.24
Sortino RatioSortino RatioLike Sharpe, but only penalizes downside volatility — a more accurate risk measure for asymmetric return distributions.Click for full definition →
-0.33
Ann. VolatilityAnnualized VolatilityThe annualized standard deviation of an asset's returns — a measure of how much prices fluctuate.Click for full definition →
27.3%
Best YearBest & Worst YearThe single calendar year with the highest and lowest return in the measured period.Click for full definition →
2025 · +19.2%
Worst YearBest & Worst YearThe single calendar year with the highest and lowest return in the measured period.Click for full definition →
2026 · -26.4%
% Positive Years% Positive YearsThe percentage of calendar years in the measurement period where the asset delivered a positive return.Click for full definition →
50%

Annual Returns

Rolling 12-Month Returns

Rolling 12-Month Annualised Volatility

Historical Drawdowns

Monthly Returns

Monthly Returns Heatmap

YearJanFebMarAprMayJunJulAugSepOctNovDecAnn.
2026-6.4-14.4-10.83.0————————-26.4%
20251.93.32.3-3.5-1.4-1.2-0.2-15.729.53.13.11.719.2%
2024——0.4-0.5-0.9-0.41.7-0.81.4-0.30.30.51.4%

Risk X-RayiA 19-factor macroeconomic risk decomposition showing exactly which market forces (equity beta, rates, inflation, credit, commodity, crypto) drive this asset's volatility. Powered by multivariate regression against daily factor returns.

Risk Profile Insight: This asset has an estimated annualized volatility of 116.0%. The dominant macroeconomic risk driver is SHV.US, accounting for 79.1% of variance. Idiosyncratic stock-specific factors contribute 2.0%.

10-Year Historical Price Series (Growth of $10,000)
DateSimulated Value
2024-02-0110000
2024-03-0110038.610003068143
2024-04-019990.348189634278
2024-05-019903.475452597184
2024-06-019864.86544952904
2024-07-0110028.958192702421
2024-08-019951.738186566135
2024-09-0110086.872737037094
2024-10-0110057.915464869759
2024-11-0110086.872737037094
2024-12-0110135.135471006044
2025-01-0110328.185486346762
2025-02-0110666.02370359433
2025-03-0110907.336452903997
2025-04-0110521.235501687479
2025-05-0110376.448220315713
2025-06-0110250.965480210474
2025-07-0110231.660938943945
2025-08-018629.343915313717
2025-09-0111177.606548023809
2025-10-0111525.09690702973
2025-11-0111882.239776008038
2025-12-0112084.942485428159
2026-01-0111312.741687637224
2026-02-019681.467502303869
2026-03-018638.996425286105
2026-04-018899.614194540545
Annual Return Matrix
YearAnnual Return
20250.19238095238095232
2026-0.2635782747603833
Total Factor Risk
1.1604623708453166
VTI.US Exposure
0.11499809950620093
VEA.US Exposure
0.00029735700997046547
VWO.US Exposure
0.0005784486769790059
QQQ.US Exposure
0.00007619863654477432
VTV.US Exposure
0.006451108690318677
IJR.US Exposure
0.006755010216069945
QUAL.US Exposure
-0.0005157390749243979
SHV.US Exposure
0.7905973413241492
TLT.US Exposure
0.011964079230999493
LQD.US Exposure
-0.00035074624471300516
HYG.US Exposure
0.008763798299891412
GLD.US Exposure
0.0000429566806044313
USO.US Exposure
0.007623362209894155
VNQ.US Exposure
0.0004254794809333439
BTC-USD.CC Exposure
-0.00005781481595745316
CPER.US Exposure
0.002985841083349873
VIX.INDX Exposure
0.00624896676213373
UUP.US Exposure
0.0002264156618305425
TIP.US Exposure
0.023325504820775566
Idiosyncratic Exposure
0.01956433184494937
Value Score
50
Growth Score
50
Profit Score
37.5
Health Score
23.6
Yield Score
0
Moat Score
40

Factor Risk Decomposition

Share of annualised volatility attributable to each macro factor.

Total Est. Vol
116.0%

FundamentalsiCompany financial health metrics: P/E valuation, dividend yield, Piotroski F-Score (9-point profitability signal), Altman Z-Score (bankruptcy risk proxy), and a radar chart across 6 fundamental dimensions. Note: ETFs may show N/A for some metrics.

Fundamental Dimensions

Core Valuation

P/E Ratio (TTM)P/E RatioPrice-to-Earnings ratio — the market price of a stock divided by its earnings per share, a key valuation measure.Click for full definition →N/A
Dividend YieldDividend YieldAnnual dividend paid per share divided by the current share price — expressed as a percentage income return.Click for full definition →0.00%
Market Cap$713.1M
Piotroski F-ScorePiotroski F-ScoreA 9-point scoring system evaluating a company's financial strength across profitability, leverage, and operating efficiency.Click for full definition →
9-point profitability signal
0.0/ 9
Weak
Altman Z-ScoreAltman Z-ScoreA bankruptcy prediction model that combines 5 financial ratios into a single score indicating financial distress risk.Click for full definition →
Bankruptcy risk proxy
1.18
Distress Zone
Income Simulation

Based on $10,000 initial investment.

Total Income Generated
$0
Avg Yield on Cost
0.00%

Momentum & MacroiPrice momentum indicators relative to key technical levels: distance from 50-Day SMA (intermediate trend), 200-Day SMA (long-term trend), 52-Week High (bullish proximity), and Beta (market sensitivity coefficient).

vs 50-Day SMAMoving Averages (SMA)A rolling average of an asset's price over a defined window — used to identify trends and momentum signals.Click for full definition →
-5.1%
Above/below 50-day moving average
vs 200-Day SMAMoving Averages (SMA)A rolling average of an asset's price over a defined window — used to identify trends and momentum signals.Click for full definition →
-16.0%
Above/below 200-day moving average
vs 52-Week High52-Week HighThe highest price an asset reached in the past 52 weeks — a key reference for momentum and valuation context.Click for full definition →
32.8% from high
Distance from 52-week high
BetaBetaA measure of an asset's sensitivity to broad market movements relative to a benchmark (e.g. S&P 500).Click for full definition →
0.51
Market sensitivity coefficient

Frequently Asked Questions & Methodology

Is BridgeBio Oncology Therapeutics, Inc. a high-risk investment?

BridgeBio Oncology Therapeutics, Inc. (BBOT.US) has an annualized volatility of 116.0% and experienced a maximum drawdown of 28.5% over the last 10 years. Its primary macro risk driver is SHV.US.

What is the 10-year return of BBOT.US?

Over the past 10 years, BBOT.US has generated a Compound Annual Growth Rate (CAGR) of -5.2%. It has had a positive return in 50% of the years measured.

Data Methodology & Trust

The risk and return information on this page is pre-calculated mathematically using daily market data spanning a 10-year period. Fundamentals (such as P/E Ratio, Market Cap, and Dividend Yield) represent trailing averages and may not immediately reflect real-time live market fluctuations. Advanced scoring models like the Piotroski F-Score and Altman Z-Score are proxies applied to publicly available trailing-twelve-month financial statements and may not account for recent off-balance-sheet events, qualitative company shifts, or sector-specific capital structures. Macroeconomic factor exposures are estimated via multivariate regression against standard market indices. This data is provided for quantitative insight and backtesting research, and should not be misconstrued as tailored financial advice.

Run a Full Backtest on BridgeBio Oncology Therapeutics, Inc.

stresstest.pro lets you simulate DCA vs Lump Sum, Monte Carlo projections, portfolio optimisation, and more — all in seconds.

Start a Free Backtest